Telor Ophthalmic Pharmaceuticals Inc. news

Following its decision to discontinue development of Tekron ethacrynic acid for the treatment of glaucoma, the Wilmington, Mass., company will cut its workforce to 30 from 43. In addition, Stephen Riggi has resigned as chief executive officer. ...